Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
Morteza Abyadeh(Virginia Commonwealth University), Mehdi Mirzaei(AGRF Ltd), Veer Bala Gupta(University of Washington), Nitin Chitranshi(Macquarie University), Samran Sheriff(Macquarie University), Vivek Gupta(Deakin University), Paul A. Haynes(Macquarie University), Ardeshir Amirkhani(AGRF Ltd), Stuart L. Graham(The University of Sydney), Kunal Dhiman(Deakin University), Ting Shen(Sungkyunkwan University), Ghasem Hosseini Salekdeh(Macquarie University), Yunqi Wu(AGRF Ltd), Anna Meyfour(Research Institute for Endocrine Sciences)
Cited by 62
Related Papers
The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis
|The Lancet Public Health|2022|350
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
|EClinicalMedicine|2023|132
Amyloid-beta and tau protein beyond Alzheimer’s disease
|Neural Regeneration Research|2023|98
AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from<i>Andrographis paniculata</i>
|Evidence-based Complementary and Alternative Medicine|2013|71
Mitochondrial dysfunction in Alzheimer’s disease - a proteomics perspective
|Expert Review of Proteomics|2021|49